• Chart
  • Rating
  • Financials
  • Technicals
  • Volume
  • Result
  • Synopsis
  • Corp Action
  • MF Shareholding
  • Similar Stocks
  • FAQs
    1. Home
    2. Stocks
    3. Neulandlab Share Price

    Neuland Laboratories Share PriceNeuland Laboratories

    Mid Cap 6k Result
    ₹5,126.7
    -186.05 (-3.5%)
    As on 06 December, 2023 | 03:24 BSE: 524558 NSE: NEULANDLABISIN: INE794A01010

    Neuland Laboratories Performance

    Day Range

    • Low 5,109.00
    • High 5,329.90
    ₹ 5,126.7

    52 Week Range

    • Low 1,318.10
    • High 5,601.40
    ₹ 5,126.7
    • Open Price5,325.00
    • Previous Close5,312.75
    • Volume65142

    Start SIP in Neuland Laboratories

    Start SIP

    Neuland Laboratories Share Price

    • Over 1 Month 32.59%
    • Over 3 Month 37.27%
    • Over 6 Month 81.78%
    • Over 1 Year 200.4%

    Neuland Laboratories Key Statistics

    P/E Ratio 24.7
    PEG Ratio 0.1
    Market Cap Cr 6,578
    Price to Book Ratio 6.7
    EPS 127.7
    Dividend 0.2
    Relative Strength Index 56.47
    Money Flow Index 62.86
    MACD Signal 306.09
    Average True Range 239.26

    Neuland Laboratories Investment Rating

    • Master Rating:

    • Neuland Laboratories has an operating revenue of Rs. 1,457.07 Cr. on a trailing 12-month basis. An annual revenue growth of 26% is outstanding, Pre-tax margin of 18% is great, ROE of 16% is good. The company has a reasonable debt to equity of 7%, which signals a healthy balance sheet. The stock from a technical standpoint is comfortably placed above its key moving averages, around 21% and 70% from 50DMA and 200DMA. It has recently broken out of a base in its weekly chart and is trading around 26% from the pivot point (which is extended from the ideal buying range for a stock). From an O'Neil Methodology perspective, the stock has an EPS Rank of 99 which is a GREAT score indicating consistency in earnings, a RS Rating of 94 which is GREAT indicating the outperformance as compared to other stocks, Buyer Demand at A which is evident from recent demand for the stock, Group Rank of 75 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of A is the best. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has great fundamentals and technical strength to stay in momentum.

    EPS Strength

    Price Strength

    Buyer Demand

    Group Rank

    Neuland Laboratories Financials
    IndicatorSep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022
    Oper Rev Qtr Cr 418363407269294221256
    Operating Expenses Qtr Cr 280266287215225193217
    Operating Profit Qtr Cr 1379712054692839
    Depreciation Qtr Cr 15141313131312
    Interest Qtr Cr 4243333
    Tax Qtr Cr 32212681532
    Net Profit Qtr Cr 89628530381022
    IndicatorMar 2023Mar 2022
    Total Revenue Annual Cr 1,201953
    Operating Expenses Annual Cr 920809
    Operating Profit Annual in Cr 271142
    Depreciation Cr 5349
    Interest Annual Cr 1313
    Tax Annual Cr 5218
    Net Profit Annual Cr 16364
    IndicatorMar 2023Mar 2022
    Cash from Operating Activity Annual Cr 23959
    Cash from Investing Activity Annual Cr -61-94
    Cash from Financing Annual Activity Cr -13638
    Net Cash Flow Annual Cr 413
    IndicatorMar 2023Mar 2022
    Total ShareHolders Funds Annual Cr 988836
    Fixed Assets Annual Cr 798788
    Total Non Current Assets Annual Cr 819801
    Total Current Assets Annual Cr 760581
    Total Assets Annual Cr 1,5791,382
    IndicatorMar 2023Mar 2022
    Book Value Per Share Annual Rs 766648
    ROE Annual % 178
    ROCE Annual % 209
    Total Debt to Total Equity Annual --
    EBDIT Annual Margin % 2415
    IndicatorSep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022
    Oper Rev Qtr Cr 418363407269294221256
    Operating Expenses Qtr Cr 280266287215224193217
    Operating Profit Qtr Cr 1379712054692939
    Depreciation Qtr Cr 15141313131312
    Interest Qtr Cr 4243333
    Tax Qtr Cr 32212681532
    Net Profit Qtr Cr 89628531381022
    IndicatorMar 2023Mar 2022
    Total Revenue Annual Cr 1,201953
    Operating Expenses Annual Cr 919808
    Operating Profit Annual in Cr 272143
    Depreciation Cr 5349
    Interest Annual Cr 1313
    Tax Annual Cr 5218
    Net Profit Annual Cr 16464
    IndicatorMar 2023Mar 2022
    Cash from Operating Activity Annual Cr 23759
    Cash from Investing Activity Annual Cr -61-94
    Cash from Financing Annual Activity Cr -13638
    Net Cash Flow Annual Cr 403
    IndicatorMar 2023Mar 2022
    Total ShareHolders Funds Annual Cr 994841
    Fixed Assets Annual Cr 519508
    Total Non Current Assets Annual Cr 819801
    Total Current Assets Annual Cr 761583
    Total Assets Annual Cr 1,5801,383
    IndicatorMar 2023Mar 2022
    Book Value Per Share Annual Rs 771652
    ROE Annual % 168
    ROCE Annual % 209
    Total Debt to Total Equity Annual --
    EBDIT Annual Margin % 2415
    Invest in Neuland Laboratories

    Neuland Laboratories Technicals

    EMA & SMA

    Current Price
    ₹5,126.7
    -186.05 (-3.5%)
    pointer
    • Bullish Moving Average
    • ___
    • 10
    • Bearish Moving Average
    • ___
    • 6
    • 20 Day
    • ₹5,066.16
    • 50 Day
    • ₹4,584.07
    • 100 Day
    • ₹4,074.98
    • 200 Day
    • ₹3,401.06
    • 20 Day
    • ₹5,226.80
    • 50 Day
    • ₹4,407.78
    • 100 Day
    • ₹4,015.01
    • 200 Day
    • ₹3,142.63

    Neuland Laboratories Resistance and Support

    PIVOT
    ₹5,188.54
    Resistance
    First Resistance 5,268.07
    Second Resistance 5,409.43
    Third Resistance 5,488.97
    RSI 56.47
    MFI 62.86
    MACD Single Line 306.09
    MACD 258.15
    Support
    First Resistance 5,047.17
    Second Resistance 4,967.63
    Third Resistance 4,826.27

    Neuland Laboratories Delivery and Volume

    Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
    Day 70,152 5,469,050 77.96
    Week 51,555 3,714,538 72.05
    1 Month 70,210 3,139,106 44.71
    6 Month 49,653 2,533,307 51.02

    Neuland Laboratories Result Highlights

    Neuland Laboratories Synopsis

    NSE-Medical-Diversified

    Neuland Laborat is involved in the business activities of Manufacture of medicinal substances used in the manufacture of pharmaceuticals: antibiotics, endocrine products, basic vitamins; opium derivatives; sulpha drugs; serums and plasmas; salicylic acid, its salts and esters; glycosides and vegetable alkaloids; chemically pure suger etc.. Company’s Total Operating Revenue is Rs. 1191.20 Cr. and Equity Capital is Rs. 12.90 Cr. for the Year ended 31/03/2023. Neuland Laboratories Ltd. is a Public Limited Listed company incorporated on 07/01/1984 and has its registered office in the State of Telangana, India. Company’s Corporate Identification Number(CIN) is L85195TG1984PLC004393 and registration number is 004393.
    Market Cap 6,578
    Sales 1,457
    Shares in Float 0.82
    No of funds 116
    Yield 0.19
    Book Value 6.7
    U/D Vol ratio 2
    LTDebt / Equity 8
    Alpha 0.47
    Beta 1.22

    Neuland Laboratories

    Owner NameSep-23Jun-23Mar-23Dec-22
    Promoters 35.97%36.03%36.14%36.14%
    Mutual Funds 1.94%1.57%0.99%0.79%
    Foreign Portfolio Investors 21.57%20.19%18.14%17.7%
    Individual Investors 27.86%29.01%29.85%30.09%
    Others 12.66%13.2%14.88%15.28%

    Neuland Laboratories Management

    Name Designation
    Dr. Davuluri Rama Mohan Rao Executive Chairman
    Mr. Davuluri Sucheth Rao Vice Chairman & CEO
    Mr. Davuluri Saharsh Rao Vice Chairman & Mng.Director
    Dr. Christopher M Cimarusti Non Executive Director
    Mr. Humayun Dhanrajgir Ind. Non-Executive Director
    Mrs. Bharati Rao Ind. Non-Executive Director
    Dr. Nirmala Murthy Ind. Non-Executive Director
    Mr. Parampally Vasudeva Maiya Ind. Non-Executive Director
    Mr. Homi Rustum Khusrokhan Ind. Non-Executive Director
    Mr. Prasad Raghava Menon Ind. Non-Executive Director

    Neuland Laboratories Forecast

    Price Estimates

    2,000(9.8%)
    1,758(-3.5%)
    1,590(-12.7%)

    Other Analyst Rating

    Neuland Laboratories Corporate Action

    Date Purpose Remarks
    2023-11-07 Quarterly Results
    2023-08-03 Quarterly Results
    2023-05-11 Audited Results & Final Dividend
    2023-02-13 Quarterly Results
    2022-11-10 Quarterly Results
    Date Purpose Remarks
    2022-07-15 FINAL Rs.5.00 per share(50%)Final Dividend

    Neuland Laboratories MF Shareholding

    Name Amount(cr)
    Quant Small Cap Fund Growth 9,521
    WhiteOak Capital Flexi Cap Fund Regular Growth 2,375
    Motilal Oswal Nifty Microcap 250 Index Fund Regular Growth 461
    WhiteOak Capital Multi Cap Fund Regular Growth 459
    WhiteOak Capital ELSS Tax Saver Fund Regular Growth 92

    Neuland Laboratories FAQs

    What is Share Price of Neuland Laboratories ?

    Neuland Laboratories share price is ₹5,126 As on 06 December, 2023 | 03:10

    What is the Market Cap of Neuland Laboratories ?

    The Market Cap of Neuland Laboratories is ₹6577.5 Cr As on 06 December, 2023 | 03:10

    What is the P/E ratio of Neuland Laboratories ?

    The P/E ratio of Neuland Laboratories is 24.7 As on 06 December, 2023 | 03:10

    What is the PB ratio of Neuland Laboratories ?

    The PB ratio of Neuland Laboratories is 6.7 As on 06 December, 2023 | 03:10

    Q2FY23

    More Information

    CIN: L67190MH2007PLC289249 | Stock Broker SEBI Regn.: INZ000010231 | SEBI RA Regn.: INH000004680 | SEBI Depository Regn.: IN DP CDSL: IN-DP-192-2016 | AMFI REGN No.: ARN-104096 | NSE Member id: 14300 | BSE Member id: 6363 | MCX Member ID: 55945 | Investment Adviser Regn No: INA000014252 | Registered Address - IIFL House, Sun Infotech Park, Road no. 16V, Plot no. B-23, MIDC, Thane Industrial Area, Waghle Estate, Thane, Maharashtra - 400604

    *Brokerage will be levied flat fee/executed order basis and not on a percentage basis. Flat fee of Rs. 10/order is available with Power Investor & Ultra Trader Packs. Investment in securities market are subject to market risk, read all related documents carefully before investing. Digital account would be opened after all procedure relating to IPV and client due diligence is completed. If sale/ purchase value of share of Rs.10/- or less, a maximum brokerage of 25 paisa per share may be collected. Brokerage will not exceed the SEBI prescribed limit.

    Compliance Officer: Ms. Namita Godbole, Email: support@5paisa.com, Support desk helpline: 8976689766

    Contact Us

    Attention Investors

    • 1. No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.
    • 2. Message from Exchange(s): Prevent Unauthorised transactions in your account --> Update your mobile numbers/email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day. Issued in the interest of investors.
    • 3. Message from Depositories: a) Prevent Unauthorized Transactions in your demat account --> Update your mobile number with your Depository Participant. Receive alerts on your registered mobile for all debit and other important transactions in your demat account directly from CDSL on the same day issued in the interest of investors. b) KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
    ©2023, 5Paisa Capital Ltd. All Rights Reserved.
    We are ISO 27001:2013 Certified.